Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 90

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 90
---
 products, we may not be able to compete effectively in our markets. If we are unable to protect the confidentiality of our trade secrets or know -how, such proprietary information may be used to compete against us; •If we are unable to maintain effective proprietary rights for our products, we may not be able to compete effectively in our markets; and •We may in the future be subject to future claims that our employees, consultants, or independent contractors have wrongfully or unavoidably used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. 18 Risks Related to Our Financial Condition and Capital Requirements •Our financial statements for the year ended December31, 2023, contained a going concern disclosure in Note 1 regarding substantial doubt about our ability to continue as a going concern. This going concern disclosure in Note 1 of financial statements could prevent us from obtaining new financing on reasonable terms or at all and risk our ability to continue operating as a going concern. •To date, we have not generated any revenue, and we do not expect to generate any significant revenue unless and until we obtain marketing approval to commercialize Quilience and/or Nolazol. We are unable to predict the extent of future losses or when we will become profitable based on the sale of any product, if at all. Even if we succeed in developing and commercializing our product candidates, we may never generate sufficient revenue to sustain profitability. As of June30, 2024, we had an accumulated deficit of approximately $[•] million. •To date, we have not generated any revenues, have a history of losses and expect to incur losses in the foreseeable future and will need to raise substantial additional capital to successfully complete development, achieve and maintain phase 3 readiness, and seek to commercialize Quilience and/or Nolazol or other product candidates including NLS4, NLS -8, NLS -11, and NLS -12and the Aexon Labs Inc., or Aexon, platform, recently in -licensed, that we may seek to develop in the future, and such capital may not be available to us or available to us only on unfavorable terms. •As a public company, we are required to comply with extensive securities rules and regulations and Swiss governmental and Nasdaq Capital Market regulations, which are expensive, and which require significant management attention. We may voluntarily choose, or be forced to delist, from the Nasdaq Capital Market in case of non